NEOK Bio

Executive Summary

NEOK Bio is a private biotechnology company headquartered in Cambridge, Massachusetts, focused on developing next-generation bispecific antibody-drug conjugates (ADCs) for cancer therapy. Founded in 2019, the company leverages its proprietary platform to design ADCs that simultaneously target two distinct antigens on tumor cells, enhancing specificity and reducing off-target toxicity. This approach aims to overcome key limitations of conventional ADCs, such as drug resistance and narrow therapeutic windows. NEOK’s pipeline includes multiple preclinical programs targeting solid tumors, with a lead candidate expected to advance toward clinical trials in the near term. Despite being in early stages, the company benefits from its location in a vibrant biotech hub and a management team with deep expertise in ADC development.

Upcoming Catalysts (preview)

• Q4 2026IND Filing for Lead Bispecific ADC Program70% success
• Q2 2026Presentation of Preclinical Data at Major Oncology Conference (e.g., AACR 2026)90% success
• 2027Series A/B Financing Round or Licensing Partnership60% success